Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1.
about
Impact of Exercise on Innate Immunity in Multiple Sclerosis Progression and SymptomatologyExpression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1)Induction of tolerance by oral administration of beta-tubulin in an animal model of autoimmune inner ear disease.Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.Oral tolerance, an active immunologic process mediated by multiple mechanisms.Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides.Bacterial pathogens induce abscess formation by CD4(+) T-cell activation via the CD28-B7-2 costimulatory pathwayTwo decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cellsExperimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).Therapeutic potential of oral tolerance.Therapeutic vaccines in autoimmunity.TGF-β signaling via Smad4 drives IL-10 production in effector Th1 cells and reduces T-cell trafficking in EAEInhibition of experimental autoimmune encephalomyelitis by a novel small molecular weight proinflammatory cytokine suppressing drug.Induction of mucosal tolerance in SLE: a sniff or a sip away from ameliorating lupus?Colonic treatments and targets: issues and opportunities.Glatiramer acetate attenuates the activation of CD4+ T cells by modulating STAT1 and -3 signaling in glia.Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease.Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update.Mycobacterial escape from macrophage phagosomes to the cytoplasm represents an alternate adaptation mechanism.Synapsin-induced proliferation of T-cell lines against myelin basic protein obtained from rats with experimental autoimmune encephalomyelitis.Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance.Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis.Protection from EAE by IL-4Ralpha(-/-) macrophages depends upon T regulatory cell involvement.Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia.Consistent induction of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice for the longitudinal study of pathology and repair.Methods for the in vitro determination of an individual disposition towards TH1- or TH2-reactivity by the application of appropriate stimulatory antigens.
P2860
Q26745562-E76D1C3A-12F2-4911-A389-7F29E2CC1D5AQ28362973-7E61CB1C-4E5F-412B-8F48-2C6ADA96B83AQ30480826-C1D0F973-1134-49F2-BFB0-8FDB65AA866BQ33546205-90B0B1A1-83AA-498A-A757-E13EF9000ABCQ33921576-67A5558D-E4E9-44EE-981E-43140F6ACD61Q33931083-EEFF3E0C-F181-4733-9C87-E5D03A22DF63Q34005152-8988FD98-D5E3-4380-A1B8-2B539790EEBFQ34090086-6C940845-2DA9-41AB-BC38-667225EC3301Q35160777-E1E38D41-7881-43E0-9896-0B02BC1CE15BQ35589934-85E7736E-51FD-43E7-BBAB-99BF88B77CF1Q35790348-356A4F97-EBE3-4E23-9DAB-8FC5E6F12060Q35861944-B6F9D928-A36B-4F8E-94F3-1370185795C0Q36340416-7AD8260A-10C5-464D-BE57-A5FE332953D0Q37040035-20E54318-A4BF-4D1C-8610-A2A93CCE5578Q37120570-24AE2AE1-42FF-41D8-9002-AB6574F38A0CQ37530912-B8B2C0F2-9F4B-4BE8-8A81-D09361475520Q37589284-D244F379-51C4-4697-A178-97491D7FE8A0Q37730171-50CF5749-3198-46E2-9A81-6DA034D7B05BQ37732340-7B0D9838-826F-4398-AEB6-C260BC0B7AB5Q38786048-48558F91-4045-451E-AD57-B00E514FA68DQ39779675-51EFE76B-C0A8-4C48-8212-4D842ADAD334Q44896920-F226884D-0D49-4CB6-83E1-48E4AE2DE0D4Q45242443-A6B5CFEB-224C-431C-967A-E0AC85B05886Q47674870-CFA619FD-6A93-4F51-8FCC-5305A004FEA6Q48384113-9C13B7C1-5459-4066-8099-334F7715B9C2Q51064476-4E12937D-75CA-43E3-91A2-B027922FA916Q53779710-3D055550-3D38-4046-8DA8-9B12F2E0490E
P2860
Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Immunomodulation of experiment ...... administration of copolymer 1.
@ast
Immunomodulation of experiment ...... administration of copolymer 1.
@en
type
label
Immunomodulation of experiment ...... administration of copolymer 1.
@ast
Immunomodulation of experiment ...... administration of copolymer 1.
@en
prefLabel
Immunomodulation of experiment ...... administration of copolymer 1.
@ast
Immunomodulation of experiment ...... administration of copolymer 1.
@en
P2093
P2860
P356
P1476
Immunomodulation of experiment ...... administration of copolymer 1.
@en
P2093
P2860
P304
P356
10.1073/PNAS.96.7.3842
P407
P577
1999-03-01T00:00:00Z